These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7950157)

  • 1. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
    Jaspers C; Benker G; Reinwein D
    Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V; Freneau E; Morange I; Simonetta C
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.
    Barnett PS; Dawson JM; Butler J; Coskeran PB; Maccabe JJ; McGregor AM
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):307-16. PubMed ID: 1977537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
    Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
    BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.
    Liu S; Hu C; Peters J; Tsang A; Cremers S; Bies R; Page-Wilson G
    Br J Clin Pharmacol; 2019 Feb; 85(2):366-376. PubMed ID: 30362146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.